Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi
In today's Pharmaceutical Executive Daily, the FDA grants accelerated approval to BeOne Medicines' Beqalzi as the first and only BCL2 inhibitor for r…
1 month, 4 weeks ago
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
In today's Pharmaceutical Executive Daily, Rigel Pharmaceuticals enters an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu, …
2 months ago
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
In today's Pharmaceutical Executive Daily, GSK enters an exclusive collaboration with Sino Biopharmaceutical's CTTQ subsidiary to accelerate the laun…
2 months ago
Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA
In today’s Pharmaceutical Executive Daily, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine ho…
2 months ago
Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement
In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst Pharmaceuticals, Incyte presents 24…
2 months ago
Strengthening the Generic Drugs Supply Chain
Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs pipeline is under stress.
2 months, 1 week ago
Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial
In today's Pharmaceutical Executive Daily, Bayer agrees to acquire Perfuse Therapeutics for up to $2.45 billion and Madrigal obtains an exclusive glo…
2 months, 1 week ago
Pharmaceutical Executive Daily: BioNTech Reports 2026 First Quarter Results
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech release…
2 months, 1 week ago
Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics
In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commenta…
2 months, 1 week ago
Pharmaceutical Executive Daily: FDA Approves Auvelity
In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk profile for AstraZeneca's Truq…
2 months, 1 week ago